{"id":286415,"date":"2026-10-05T11:23:02","date_gmt":"2026-10-05T05:53:02","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=286415"},"modified":"2026-10-05T11:23:02","modified_gmt":"2026-10-05T05:53:02","slug":"novartis-india-share-price-chryscapital-open-offer","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/novartis-india-share-price-chryscapital-open-offer\/","title":{"rendered":"Novartis India Share Price Jumps Up to 10% on 5 October: How a ChrysCapital Takeover, a Rs 860.64 Open Offer Almost Nobody Used and a New Retina Drug Deal Put the Stock at 2.5 Times the Offer Price"},"content":{"rendered":"

Novartis India up to 10% on 5 Oct, day high Rs 2,164.60. Open offer Rs 860.64 drew only 40 shares. ChrysCapital owns 71%. P\/E about 50. Support Rs 1,900.<\/em><\/p>\n

\n

Quick Answer<\/strong><\/p>\n

Novartis India share price jumped between 7% and nearly 10% on 5 October, reaching an intraday high of Rs 2,164.60, about 2.5 times the Rs 860.64 open offer price that the new ChrysCapital-led owners paid in the takeover. Public shareholders tendered only 40 shares in that offer because the market price was far higher. The company has Rs 668 crore of net cash, a new retina medicine distribution deal and a P\/E near 50 on flat revenue of about Rs 354 crore. Analysts say the stock needs to hold above Rs 2,100 for momentum, with support near Rs 1,900.<\/p>\n<\/p><\/div>\n

The Novartis India share price today has become one of the most volatile small caps in the market. It traded near Rs 830 in February, hit a 20% upper circuit at Rs 996.50 when the Swiss parent agreed to sell, and is now above Rs 2,100. On 5 October the stock rose as much as 7.3% to Rs 2,164.60 against a Sensex gain of 0.8%, a stock-specific move on top of the broader market recovery.<\/p>\n

If you are searching for what lies ahead for the Novartis India stock, this article covers the ChrysCapital takeover and the Novartis India open offer, the business and its net cash, the Q1 FY27 results, the Accentrix and Pagenax distribution deal and its entry into ophthalmology, valuation, P\/E and market capitalisation, the 52-week high, support and key levels, and the risks. Price data is based on NSE and BSE figures, so recheck it before acting.<\/p>\n

Click Here – Get Free Investment Predictions<\/a><\/strong><\/p>\n

\n
\n

Table of Contents<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n